CMS HIV Testing Coverage Policy Updated: What Billing Teams Need to Know About NCD 46

CMS has modified National Coverage Determination (NCD) 46, which governs Medicare coverage for HIV testing used in prognosis and monitoring—including plasma HIV RNA quantification and viral load testing. This update, effective March 12, 2026, refines the indications, limitations, and frequency standards for covered HIV viral load testing under the Diagnostic Laboratory Tests benefit category. If your practice or lab bills Medicare for HIV monitoring services, this policy directly affects how you document medical necessity and establish compliant testing frequencies.

What CMS NCD 46 Covers for HIV Viral Load Testing

The Centers for Medicare & Medicaid Services covers HIV plasma RNA quantification—commonly called viral load testing—as a medically necessary service for confirmed HIV-positive Medicare beneficiaries. These assays use nucleic acid amplification techniques to measure circulating viral RNA and express results as HIV copy number.

CMS recognizes two primary clinical purposes for this testing: prognostic assessment of disease progression risk, and monitoring the efficacy of antiretroviral therapy (ART) over time. Viral load testing is also commonly ordered alongside CD4+ T cell counts, which measure the extent of immune system damage already incurred from HIV infection.

The policy classifies this testing under the Diagnostic Laboratory Tests benefit category. Note that this policy governs prognostic and monitoring use only—it explicitly excludes viral load testing as a primary diagnostic method for HIV infection.

CMS Medical Necessity Criteria for HIV Plasma RNA Testing

CMS outlines three core indications under NCD 46 where plasma HIV RNA testing may be medically necessary:

Indication 1 — Baseline testing for confirmed HIV infection:
Any patient with confirmed HIV infection may qualify for a plasma HIV RNA baseline level measurement. This is the starting point for all subsequent monitoring.

Indication 2 — Periodic monitoring for disease management:
Regular, periodic plasma HIV RNA measurement is covered to assess risk for disease progression and to guide decisions about initiating or modifying antiretroviral treatment regimens. The frequency of testing must be consistent with current CDC guidelines for antiretroviral agents in adults, adolescents, or pediatric patients—not an arbitrary internal protocol.

Indication 3 — Pre-treatment baseline in anticipated therapy scenarios:
CMS covers baseline HIV quantification in clinical situations where HIV infection risk is significant and therapy initiation is anticipated. Two specific scenarios qualify:

These indications are not interchangeable. Your documentation must map clearly to one of these three scenarios to support medical necessity on the claim.

Key Limitations Billing Teams Must Understand

NCD 46 includes five limitations that directly affect how claims should be submitted and documented:

1. Not for diagnosis—only prognosis and monitoring.
Viral load testing cannot be billed as a diagnostic tool for determining whether a patient has HIV. Coverage applies to prognostic use, baseline determination, and therapy monitoring only.

2. Two-specimen baseline protocol.
For an accurate baseline, CMS specifies that two specimens collected within a two-week period are appropriate. Billing teams should ensure both specimens are documented with the correct collection dates and that the clinical record supports the two-specimen baseline rationale.

3. Testing frequency must follow CDC guidelines.
CMS does not define a specific number of tests per year—it defers to the most current CDC guidelines for antiretroviral therapy in adults, adolescents, and pediatric patients. This means your internal testing frequency protocols must be benchmarked against current CDC guidance, and that guidance should be referenced in documentation supporting medical necessity.

4. Assay consistency matters for coverage.
Because absolute HIV copy numbers vary between assay types, CMS requires that plasma HIV RNA levels be measured by the same analytical method throughout a patient's monitoring. If your lab changes assay methods, a new baseline must be established. This has billing implications—a change in assay may justify additional baseline specimens that would otherwise appear duplicative.

5. FDA-approval status of nucleic acid quantification technologies.
CMS flags that nucleic acid quantification techniques are evolving rapidly. The policy advises users to remain current on FDA-approval status for the specific assays being used. Billing for a test performed with a non-FDA-approved method creates a coverage and compliance risk.

Affected Codes

This policy does not list specific CPT or HCPCS codes in the policy document. CMS directs users to the quarterly Covered Code Lists—including narrative descriptions—which are linked within the full NCD 46 document on the CMS website. For current, applicable billing codes, billing teams should consult those quarterly lists directly and cross-reference with the Medicare Claims Processing Manual, Chapter 120, Clinical Laboratory Services Based on Negotiated Rulemaking.

No ICD-10-CM diagnosis codes are specified in the policy data for this NCD.

Action required: Pull the most recent quarterly Covered Code List associated with NCD 46 to identify the exact CPT/HCPCS codes applicable to your claims before the March 12, 2026 effective date.

What Your Billing Team Should Do